Status:
APPROVED_FOR_MARKETING
Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer
Lead Sponsor:
University of California, San Francisco
Conditions:
Prostate Cancer
Prostate
Eligibility:
MALE
18+ years
Brief Summary
This expanded access protocol provides eligible participants with investigational 68Ga-PSMA-11 PET imaging to detect and localize prostate cancer for initial and subsequent treatment strategy.
Eligibility Criteria
Inclusion
- Biochemical recurrent and pre-prostatectomy staging participants will be eligible and must meet the following criteria:
- Age ≥ 18 years
- Histopathologically confirmed or biopsy proven prostate adenocarcinoma.
- Concern for metastatic disease in one of the following settings:
- Initial staging with intermediate to high risk prostate cancer.
- Biochemical recurrence after initial therapy.
- Ability to understand a written informed consent document, and the willingness to sign it
Exclusion
- 1\. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04377152
Last Update
March 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143